StockData
Aardvark Therapeutics, Inc. logo

Aardvark Therapeutics, Inc. (AARD) stock

AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.33−0.19 (-12.50%)

Close on Nov 13, 2026Market cap $29.11MP/E –Yield –

Aardvark Therapeutics statistics

58 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
Mar 22, 2027 (estimated, after the close)
Last ex-dividend date
No dividends
Fundamentals through
Sep 30, 2026
Share price as of
Nov 13, 2026

Valuation ratiosIndustry

Market Cap
$29.11M
$272.32M
Enterprise Value
-$31.19M
$146.23M
PB Ratio
0.51
2.00
P/TBV Ratio
0.51
2.22

Share statisticsIndustry

Shares Change (YoY)
44.0%
10.8%
Shares Change (QoQ)
0.02%
0.50%
Float
13M
49M
Shares Held by Insiders
41.9%
11.7%
Shares Held by Institutions
43.6%
56.4%

Short sellingIndustry

Short Interest
1M
–
Short Interest Change
87.8%
-0.80%
Short % of Float
8.17%
9.01%
Short % of Shares Outstanding
4.75%
6.30%
Days to Cover
1.00
5.15

Stock price statisticsIndustry

52-Week High
$16.60
–
52-Week Low
$0.93
–
20-Day Moving Average
$1.86
–
50-Day Moving Average
$3.76
–
200-Day Moving Average
$5.65
–
Average True Range (14)
$0.36
–
Price Change (1 Week)
13.7%
-1.15%
Price Change (1 Month)
-65.5%
-4.87%
Price Change (3 Months)
-80.3%
-21.0%
Price Change (6 Months)
-70.9%
-20.6%
Price Change (YTD)
-89.9%
-23.6%
Price Change (1 Year)
-87.6%
-22.4%
Average Volume (10 Days)
339,771
–
Average Volume (20 Days)
2M
–
Average Volume (90 Days)
537,145
–
Relative Volume
0.75
0.70
Relative Strength Index (14)
31.6
43.4
Volatility (1 Year)
149.2%
80.1%

Returns on capitalIndustry

Return on Equity (ROE)
-80.9%
-49.9%
Return on Assets (ROA)
-73.5%
-40.6%
Return on Capital Employed (ROCE)
-131.5%
-37.9%

Financial positionIndustry

Current Ratio
9.11
3.30
Quick Ratio
8.57
2.39

EfficiencyIndustry

Asset Turnover
0.00
0.40
Revenue Per Employee
$0
$429.29K
Profits Per Employee
-$1.82M
-$689.41K
Employee Count
40
74

Income statement (TTM)Industry

Revenue
$0
$66.37M
Operating Income
-$75.97M
-$21.37M
Net Income
-$72.76M
-$22.35M
EBITDA
-$75.93M
-$17.21M
EPS (Diluted)
-$3.34
-$0.76

Balance sheetIndustry

Net Cash (Debt)
$60.30M
$17.76M
Net Cash Per Share
$2.76
$0.80
Equity (Book Value)
$57.61M
$53.89M
Book Value Per Share
$2.63
$1.50
Tangible Book Value
$57.61M
$27.13M
Working Capital
$57.07M
$79.99M

Cash flow (TTM)Industry

Operating Cash Flow
-$66.81M
-$12.38M

Dividends and yieldsIndustry

Earnings Yield
-250.0%
-21.8%

Scores and fair valueIndustry

Altman Z-Score
-4.08
0.23
Piotroski F-Score
2
4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.

PeriodAARDS&P 500DifferenceAARD per yearS&P 500 per year
1 month-67.1%-3.0%−64.0 pts
3 months-79.3%-2.8%−76.5 pts
Year to date-89.9%+11.5%−101.4 pts
1 year-87.8%+13.5%−101.2 pts
3 years+280.0%+77.7%+202.3 pts+56.0%+21.1%
5 years+280.0%+72.6%+207.4 pts+30.6%+11.5%
10 years+280.0%+308.2%−28.2 pts+14.3%+15.1%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

1M AARD shares were sold short on Oct 30, 2026, up 87.8% from the previous report, or 8.17% of the shares available to trade. At recent volumes it would take 1.0 days to buy them back. Over the last 20 sessions, 55.2% of the volume reported to FINRA was short selling.

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 20261,038,938+87.8%2,760,0641.0
Oct 15, 2026553,262+16.7%152,3813.6
Sep 30, 2026474,080+11.6%89,6315.3
Sep 15, 2026424,912-16.7%149,5722.8
Aug 31, 2026509,891-16.7%135,1073.8
Aug 14, 2026611,764-6.2%116,5885.3
Jul 31, 2026652,496+0.1%145,3594.5
Jul 15, 2026651,789+23.4%675,7011.0
Jun 30, 2026528,265-42.1%312,1751.7
Jun 15, 2026911,832-7.7%131,0027.0
May 29, 2026987,661-2.6%178,1095.5
May 15, 20261,013,637-19.7%183,6665.5

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?